Monday, December 4, 2023
Clinical Advances in
Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy that uses the body's own immune system to target cancer cells. The therapy involves engineering the patient's own T cells to produce synthetic molecules on their surface that can specifically recognize and attack cancer cells. Clinical Advances in CAR T-Cell Therapy in Multiple Myeloma provides education on the rationale, methodology, and evidence for this therapy, and its implications for clinical practice.
Supported by an independent educational grant from
Find the most current information on new and emerging CAR T-cell treatment options for patients with multiple myeloma.
Download
Steering Committee Chair
University Professor of Clinical Hematology
Head, Hematology Department
University Hospital of Nantes
Nantes, France
Professor, Director
University Hospital Wuerzburg
Wuerzburg, Bavaria, Germany
Kraft Family Chair and Professor of Medicine
Dana Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts, United States
Director, Center for Myeloma Massachusetts General Hospital Boston, Massachusetts, United States
Consultant Clinica Universidad de Navarra University of Navarra Pamplona, Navarra, Spain
Associate Professor of Medicine
University of California San Francisco
United States
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Roche; Sanofi
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: : AbbVie Inc.; Adaptive Biotechnologies; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Karyopharm; OncoPep, Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Celgene Corporation; Janssen Pharmaceuticals
Owns stock, stock options, or bonds from: OncoPep, Inc.
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: bluebird bio, Inc.
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals; Kite Pharma Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Indapta Therapeutics, Inc.; Karyopharm; Nektar Therapeutics; Oncopeptides AB; Precision Therapeutics; Sanofi; Seattle Genetics, Inc.; Surface Oncology
Received grants for clinical research from: bluebird bio, Inc.; Celgene Corporation; Janssen Pharmaceuticals; Sutro Biopharma, Inc.; TeneoBio
Owns stock, stock options, or bonds from: Indapta Therapeutics, Inc.